Atazanavir

Major

Atazanavir Anagrelide Agrylin Increased risk of QT interval prolongation Details Atazanavir Avanafil Stendra Decreased avanafil clearance and increased avanafil plasma concentrations Details Atazanavir Axitinib Inlyta Increased axitinib plasma concentrations Details Atazanavir Bedaquiline Sirturo Increased bedaquiline exposure and an increased risk of QT interval prolongation Details Atazanavir Bosutinib Bosulif Increased bosutinib exposure Details Atazanavir Brentuximab Vedotin Injection Adcetris Increased exposure to active entity of brentuximab vedotin Details Atazanavir Brexpiprazole Rexulti Increased brexpiprazole exposure Details Atazanavir Brigatinib Alunbrig Increased brigatinib exposure Details Atazanavir Budesonide Entocort Increased budesonide exposure Details Atazanavir Budesonide Nasal Spray Rhinocort Increased budesonide exposure Details Atazanavir Budesonide Oral Inhalation Pulmicort Increased budesonide exposure Details Atazanavir Cabazitaxel Injection Jevtana Increased cabazitaxel exposure Details Atazanavir Cabotegravir Apretude Loss of virologic response and possible development of viral resistance Details Atazanavir Chloroquine Aralen® Increased risk of QT-interval prolongation Details Atazanavir Ciclesonide Nasal Spray Omnaris Increased corticosteroid exposure and an increased risk of corticosteroid-related adverse effects Details Atazanavir Ciclesonide Oral Inhalation Alvesco Increased corticosteroid exposure and an increased risk of corticosteroid-related adverse effects Details Atazanavir Clopidogrel Plavix Reduced clopidogrel (active metabolite) exposure and reduced efficacy of clopidogrel Details Atazanavir Cobimetinib Cotellic Increased cobimetinib plasma concentrations Details Atazanavir Cyclophosphamide Cytoxan® Increased risk of chemotherapy-induced mucositis, neutropenia, and infection Details Atazanavir Cyclophosphamide Injection Cytoxan® Injection Increased risk of chemotherapy-induced mucositis, neutropenia, and infection Details Atazanavir Dabigatran Pradaxa® Increased dabigatran etexilate exposure and an increased risk of bleeding Details Atazanavir Dabigatran Etexilate Increased dabigatran etexilate exposure and an increased risk of bleeding Details Atazanavir Dasatinib Phyrago Increased dasatinib exposure and an increased risk of QT interval prolongation Details Atazanavir Deflazacort Emflaza Increased exposure to active metabolite of deflazacort Details Atazanavir Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Atazanavir Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Atazanavir Dexamethasone Injection Decadron Reduced atazanavir exposure, reduced efficacy of atazanavir, increased dexAMETHasone exposure and increased risk of dexAMETHasone-... Details Atazanavir Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced atazanavir exposure, reduced efficacy of atazanavir, increased dexAMETHasone exposure and increased risk of dexAMETHasone-... Details Atazanavir Dexlansoprazole Dexilant Reduced atazanavir exposure, reduced efficacy of atazanavir and development of resistance Details Atazanavir Didanosine Videx® Reduced solubility and exposure to atazanavir with the didanosine buffered formulation and reduced didanosine exposure with enteri... Details Atazanavir Disopyramide Norpace Increased antiarrhythmic exposure and an increased risk of QT interval prolongation Details Atazanavir Docetaxel Beizray An increased risk of DOCEtaxel exposure Details Atazanavir Docetaxel Injection Beizray An increased risk of DOCEtaxel exposure Details Atazanavir Dofetilide Tikosyn An increased risk of QT interval prolongation Details Atazanavir Dolasetron Anzemet An increased risk of QT interval prolongation Details Atazanavir Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Atazanavir Doxorubicin Adriamycin Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Atazanavir Edoxaban Savaysa Increased edoxaban exposure and an increased risk of bleeding Details Atazanavir Elacestrant Orserdu Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Atazanavir Eluxadoline Viberzi Increased eluxadoline exposure Details